Comparison of a Trauma Comorbidity Index with Other Measures of Comorbidities to Estimate Risk of Trauma Mortality

Peter C. Jenkins, MD, MSc,¹ Brian E. Dixon, PhD,^{2,3} Stephanie A. Savage, MD, MPH,⁴ Aaron E. Carroll, MD, MPH,^{2,5} Craig D. Newgard, MD, MPH,⁶ Christopher J. Tignanelli, MD,^{7,8,9} Mark R. Hemmila, MD,¹⁰ Lava Timsina, PhD¹

¹Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA, <u>pecjenki@iu.edu</u>; ²Regenstrief Institute, Indianapolis, IN, USA; ³Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA, <u>bedixon@regenstrief.org</u>; ⁴Department of Surgery, University of Wisconsin, Madison, WI, USA, <u>savage@surgery.wisc.edu</u>; ⁵Pediatric and Adolescent Comparative Effectiveness Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA, <u>aaecarro@iu.edu</u>; ⁶Department of Emergency Medicine, Oregon Health & Science University School of Medicine, Portland, OR, USA, <u>newgardc@ohsu.edu</u>; ⁷Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA; ⁸Department of Surgery, North Memorial Health Hospital, Minnesota, USA; ^oInstitute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA, <u>ctignane@umn.edu</u>; ¹⁰Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA, <u>mhemmila@med.umich.edu</u>; ¹Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA, <u>Itimsina@iu.edu</u>.

Correspondence:	Peter C. Jenkins, MD, MSc		
	Methodist Hospital		
	1604 N. Capitol Avenue, B250		
	Indianapolis IN, 46202		
	Phone: 317-962-5317		
	pecjenki@iu.edu		

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi:</u> 10.1111/ACEM.14270

Running title: Development of a Trauma Comorbidity Index

Presented at the 78th Annual Meeting of American Association for the Surgery of Trauma, September 06-08, 2019 in Dallas, TX.

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002529 and the Indiana State Department of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Indiana State Department of Health.

Authorship contributions: study concept and design (PJ, SS, LT), acquisition of the data (PJ, LT), analysis and interpretation of the data (PJ, LT), drafting of the manuscript (PJ), critical revisions (BD, AC, MH, CN, CT), statistical expertise (LT, CT, CN), and acquisition of funding (PJ).

No conflict of interest

Author N

- 2 DR. PETER C JENKINS (Orcid ID : 0000-0002-8527-8268)
- 3 DR. BRIAN E DIXON (Orcid ID : 0000-0002-1121-0607)
- 4 DR. CRAIG NEWGARD (Orcid ID : 0000-0003-1083-3455)
- 5 6

1

- 7 Article type : Original Contribution
- 8 9

10 ABSTRACT

11 **Background** Comorbidities influence the outcomes of injured patients, yet a lack of consensus 12 exists regarding how to quantify that association. This study details the development and internal 13 validation of a trauma comorbidity index (TCI) designed for use with trauma registry data and 14 compares its performance to other existing measures to estimate the association between

15 comorbidities and mortality.

16 Methods Indiana state trauma registry data (2013-2015) was used to compare the TCI with the Charlson and Elixhauser comorbidity indices, a count of comorbidities, and comorbidities as 17 18 separate variables. The TCI approach utilized a randomly selected training cohort and was 19 internally validated in a distinct testing cohort. The C-statistic of the adjusted models was tested 20 using each comorbidity measure in the testing cohort to assess model discrimination. C-statistics 21 were compared using a Wald test, and stratified analyses were performed based on predicted risk 22 of mortality. Multiple imputation was used to address missing data. 23 **Results** The study included 84,903 patients (50% each in training and testing cohorts). The 24 Indiana TCI model demonstrated no significant difference between testing and training cohorts (p = 0.33). It produced a C-statistic of 0.924 in the testing cohort, which was significantly greater 25 26 than that of models using the other indices (p < 0.05). The C-statistics of models using the 27 Indiana TCI and the inclusion of comorbidities as separate variables – the method used by the 28 American College of Surgeons Trauma Quality Improvement Program – were comparable (p =

- 29 0.11) but use of the TCI approach reduced the number of comorbidity-related variables in the
- 30 mortality model from 19 to one.

31 Conclusions When examining trauma mortality, the TCI approach using Indiana state trauma 32 registry data demonstrated superior model discrimination and/or parsimony compared to other 33 measures of comorbidities.

34

35 INTRODUCTION

Comorbidities influence the detection, prognosis, treatment, and outcomes of disease.^{1, 2} 36 37 As the U.S. population continues to age and cases of geriatric trauma become more prevalent, the influence of comorbidities on the outcomes of the trauma population is likely to grow.³ Studies 38 39 of trauma patient outcomes have long advocated for specific clinical practices, such as the 40 transfer of certain patients to highly specialized trauma centers based on the presence of comorbid conditions.^{4, 5} Moreover, quality improvement efforts, such as those of the American 41 42 College of Surgeons Trauma Quality Improvement Program (ACS TQIP), routinely include 43 comorbidities in the risk-adjusted models used to report patient outcomes and evaluate hospital quality.⁶ 44

45 Despite widespread recognition that comorbidities influence trauma care and outcomes, a 46 lack of consensus exists regarding how best to measure that influence. Virtually all U.S. trauma centers and many non-trauma hospitals maintain detailed clinical registries, which are the 47 predominant data source for trauma quality improvement initiatives.^{6,7} Yet neither of the two 48 49 most prevalent composite indices of comorbidities, the Charlson and Elixhauser comorbidity 50 indices, were designed to leverage trauma registry data; the former was developed using clinical 51 registry data from patients with non-trauma diagnoses, while the latter employed administrative 52 data. Current statistical models employed by ACS TQIP include each comorbidity as a separate 53 variable, an approach that requires considerable statistical power and consumes valuable degrees of freedom when investigating low prevalence outcomes such as mortality.⁶ 54 55 We postulate that a comorbidity index specifically developed for use with trauma registry 56 data would improve the predictive modelling of trauma mortality, particularly for hospitals and 57 patient cohorts whose case volumes cannot support the statistical demands of the ACS TOIP

approach. To test that hypothesis, in this study, we describe an approach to develop and

59 internally validate such an index, and we compare the model discrimination of that measure with

60 other, existing comorbidities measures when evaluating the mortality of injured patients.

61

62 METHODS

63 Study design

64 We conducted a retrospective cohort study of trauma patients using data from the Indiana 65 state trauma registry. Primary exposure variables included four different measures of comorbid 66 disease burden, and the outcome of interest was in-hospital mortality. The study consisted of 67 three stages: first, we developed and internally validated the trauma comorbidity index (TCI) in 68 "training" and "testing" cohorts, respectively; second, we compared the predictive value of the 69 TCI with other comorbidity measures using the testing cohort; and third, we compared model 70 specification attributable to the TCI and two other comorbidity indices using the testing cohort, 71 stratified by predicted risk of mortality.

72

73 Data Source and Study Population

74 The study cohort consisted of all patient data (ages >16 years) collected in the state 75 trauma registry by the Indiana State Department of Health (ISDH) from 2013 through 2015. All 76 diagnoses are encoded using International Classification of Diseases, Ninth Revision, Clinical 77 Modification (ICD-9-CM) codes, because ICD-10-CM codes were not included in the Indiana trauma registry until 2016.⁸ The registry includes all data fields of the National Trauma Data 78 79 Standards set by the ACS Committee on Trauma, and it consists of data from all hospitals that submit data in compliance with state rule 410 IAC 34 of the ISDH Trauma Care Committee.^{9,10} 80 81 The Indiana trauma registry is inclusive, since the rule applies to all hospitals, including both 82 trauma centers and non-trauma hospitals. To populate the registry, hospital personnel collect 83 detailed prehospital, emergency department, operative, intensive care, and hospital data for all patients with diagnoses encoded as injury and poisoning.⁸ These data are provided in an 84 85 encrypted fashion through collaboration with ISDH to ensure compliance with the Health 86 Insurance Portability and Accountability Act. 87 We excluded patients who presented to emergency departments without signs of life,

defined as an initial systolic blood pressure of 0 mmHg, heart rate of 0 beats/min, and Glasgow
Coma Scale motor score of 1.¹¹

We supplemented the data from the trauma registry with hospital-level data – number of
hospital beds, teaching status, and profit status – obtained from the American Hospital
Association (AHA) by linking the datasets using the name of each hospital identified in both

datasets.¹² For hospitals that lacked AHA data, ISDH conducted a hospital survey to directly 93 94 acquire that information so that we had comprehensive hospital data from all hospitals included 95 in the study.

96

97 **Pre-existing Comorbid Conditions and Comorbidity Indices**

98 The ISDH trauma registry provides a list of comorbid factors defined by ICD-9-CM/ ICD-10-CM codes consistent with the National Trauma Data Standards.¹³ To conduct this study, 99 100 we used four different measures of pre-existing comorbid conditions to model trauma outcomes: the Charlson comorbidity index,¹⁴ the Elixhauser comorbidity index,¹⁵ a count of comorbidities, 101 all comorbidities included as separate variables (the method used by ACS TQIP),⁶ and the TCI. 102 103 We accounted for changes that occurred to the comorbidity data collected during the study 104 period with the following two steps: 1) "pulmonary disease" was changed to "chronic obstructive 105 pulmonary disease," so we classified both diseases as "chronic obstructive pulmonary disease;" 106 and 2) the ACS COT omitted the variable "pre-hospital cardiac arrest" from the National Trauma 107 Data Standard as a pre-existing comorbid condition in 2015, so we omitted that variable from the analyses."16, 17 108

109

Charlson Comorbidity Index (CCI) 110

111 First described in 1987, the CCI was developed in a training cohort of 559 patients 112 admitted to the medical service of a single hospital and externally validated in a testing cohort of 685 patients admitted to the medical service in another hospital.¹⁴ The CCI consists of 16 113 114 diagnoses that are weighted (1, 2, 3, and 6) based on association of the comorbidity with 1-year 115 mortality. Greater weights, therefore, represent an increased association with mortality. In order 116 to generate CCI scores using trauma registry data, we identified all available comorbidity 117 diagnoses included in the CCI and weighted them accordingly. Five comorbidities included in 118 the CCI were not present in the trauma registry, and those diagnoses are listed in the Supplement, 119 eTable 2. The missing comorbidities were assigned with zero weights to compute CCI.

120

121 **Elixhauser Comorbidity Index (ECI)**

122 The ECI was first described in 1998, and it was developed using administrative data from 439 hospitals in California.¹⁵ The ECI consists of 30 diagnoses associated with increased hospital 123

124 length of stay, charges, and in-patient mortality. In the scoring system, all diagnoses are

125 weighted equally and tabulated to determine a single score.¹⁸ We identified all available

126 comorbidity diagnoses in the trauma registry that are included in the ECI. Fourteen variables

127 included in the ECI were not included in trauma registry, and those diagnoses are listed in the

Supplement, eTable 2. The missing comorbidities were assigned with zero weights to compute

- 128
- 129 ECI.
- 130

131 Trauma Count of Comorbidities (TCC)

132 We calculated a TCC by testing the unadjusted association between each comorbidity 133 included in the trauma registry and mortality through bivariate logistic regression. We then 134 tabulated all comorbidities with a $p \le 0.25$. We based this cutoff on previously published 135 methods for the development of forward stepwise regression models.¹⁹⁻²¹

136

137 Comorbidities Included Separately

We identified comorbidities that met a minimum threshold association with mortality (p ≤ 0.25) through bivariate analysis, and we included each variable separately in the mortality model, an approach consistent with the method used by ACS TQIP.⁶

141

142 Trauma Comorbidity Index (TCI)

- 143 The TCI approach used a 3-step process:
- 144 1. Identify comorbidities associated with mortality ($p \le 0.25$) based on bivariate analysis
- 145 2. Obtain coefficients for each comorbidity through multivariable regression models
- 146 3. Sum the comorbidity coefficients to create coefficient weighted TCI for each patient
- 147 Details of the multivariable model are provided below in "Risk Adjustment." Positive
- 148 coefficients derived in Step 2 denote that a comorbidity has an association with increased
- 149 mortality, and negative values denote an association with decreased mortality.
- 150

151 Risk Adjustment

152 When modeling the association between comorbidities and trauma outcomes (in-hospital

- mortality and LOS), we included the following patient-level covariates: Injury Severity Score
- 154 (ISS), Glasgow coma scale (GCS), age, gender, race, initial systolic blood pressure and pulse

155 rate in the emergency department, mechanism of injury, payer type, and transfer status.

156 Additionally, we controlled for the following hospital-level covariates: American College of

157 Surgeons trauma verification level, number of hospital beds, teaching status, and profit status.

158 We directly selected the variables listed above to develop the risk-adjusted mortality models for

this study, since they have been used previously by ACS TQIP as part of its established practice

160 for risk-adjustment.⁶

161 Analysis

162 We began by inspecting the graphic distribution of continuous variables (patient age, 163 systolic blood pressure, and heart rate) and found no skewness of the data. Additionally, we 164 checked for statistically significant outlying observations and influential datapoints using the 165 Pregibon's dbeta test and found no evidence of influential observations or datapoints that may significantly alter our conclusions.²² To reduce bias and preserve statistical power to compare 166 the comorbidity indices, we performed multiple imputation using chained equation algorithm (20 167 iterations) to address missing values.²³ We evaluated the results of imputation by examining 168 169 trace plots of the imputed values (means and standard deviations) and found no evidence of 170 violation of convergence.

In order to develop and internally validate the Trauma Comorbidity Index (TCI), we randomly divided the entire 2013-2015 cohort into training (50%) and testing cohorts (50%), We performed descriptive statistics to characterize the study cohort using Chi-square and t-test to calculate p-values for categorical and continuous variables, respectively. We elected to use this split-sample approach to validation, because the size of our training and testing cohorts was large enough (> 42,000 patients in each cohort) so the model would not suffer from unmeasured biases.²⁴

178 In the first stage of analysis, we established a baseline estimate of the mortality model by 179 performing multivariable logistic regression – omitting any comorbidity measure – using both 180 training and testing cohorts. We clustered at the hospital level to account for any hospital-level 181 association with mortality and to derive robust standard errors, and we calculated the C-statistic 182 for the mortality model in each cohort. We tested for difference between the C-statistics of the two cohorts using the Wald test.²⁵ Then, we examined how the inclusion of the comorbidity 183 184 measures impacted the predictive value of the mortality model. We calculated the TCI using the 185 method detailed above using the training cohort, included it in the adjusted model, and calculated

the C-statistic. We evaluated the internal validity of the TCI by calculating it in the testing cohort,
taking care to apply the coefficients derived from the training cohort, and we tested for
difference between the C-statistics of the two cohorts using the Wald test. Next, we repeated
these steps, substituting the TCI for each of the other measures of comorbidities. In the second
stage of analysis, we used the Wald test to compare the C-statistics of the respective mortality
models with each comorbidity measure in the testing cohort.

192 In the third stage of analysis, we compared the model specification attributable to the CCI, 193 ECI, and TCI in two different ways, given the prevalence of the two former indices in existing literature. First, using the testing cohort, we calculated the number of deaths accurately predicted 194 195 by each mortality model by 1) calculating the sensitivity of the mortality models for each dataset 196 (the original and imputed ones) using a posterior predictive command that defines "sensitivity" 197 as true positives (accurately predicted deaths) divided by all positives; 2) deriving the mean 198 sensitivity of the datasets; and 3) multiplying that mean value by the total number of deaths in 199 the unimputed testing cohort. Second, we examined how closely each comorbidity index score 200 corresponded to observed and expected mortality. We did so by 1) calculating the predicted (i.e., 201 expected) mortality for each patient using the three mortality models; 2) dividing patients into 202 deciles of predicted risk; 3) calculating the percentage of actual (i.e., observed) deaths per decile; 203 and 4) calculating the mean comorbidity index score within each decile.

204The study was approved by the Indiana University Institutional Review Board, and all205analyses were performed using Stata 15 software (StataCorp LLC, College Station, TX).

206

207 **RESULTS**

208 The cohort consisted of 84,903 patients admitted to 109 hospitals over the study period. 209 The hospitals included three Level 1 trauma centers, six Level 2 trauma centers, ten Level 3 210 trauma centers, and ninety non-trauma centers. All trauma centers had ACS verification for their 211 respective levels. Patients were predominantly elderly, white, and male, and the most commonly 212 identified mechanism of injury was falls. Patient data - demographics and injury characteristics -213 are summarized in Table 1. Approximately 65% of the patient cohort had at least one 214 comorbidity, including conditions such as "drug abuse disorder" and "current smoker," and the 215 maximum number of comorbidities was 9 (median = 1, interquartile range [IQR] = 0-2). Table 2 216 summarizes patient comorbidities. The incidence of in-hospital mortality was 2.8%.

217 When divided into training and testing cohorts, demographic, injury, and comorbidity 218 characteristics were evenly distributed between the two groups (p > 0.05).²⁶ The distribution of 219 demographic and injury characteristics between the cohorts is summarized in Table 1, and Table 220 2 summarizes the distribution of comorbid conditions used to develop the TCI. Of note, mortality 221 was also evenly distributed between the training and testing cohorts (2.9% and 2.8% respectively, 222 p = 0.82).

223 In the training cohort, we identified 19 comorbidities that met the minimum threshold 224 association with mortality using bivariate analysis (p < 0.25), and the coefficients derived from 225 the multivariable models ranged from -1.0 (drug use disorder) to 1.2 (presence of an advanced 226 directive limiting care). The TCI ranged from -1.8 to 5.1, with negative values representing a 227 decreased association with risk-adjusted mortality, relative to a TCI of zero. The p-values and 228 coefficients for each comorbidity used to develop the TCI, along with the corresponding 229 coefficient in the CCI and ECI are summarized in Table 3. Comorbidities included in the trauma 230 registry but not incorporated in the TCI are listed in Supplement, eTable 2.

Regarding internal validation of the TCI, we found no significant difference (p = 0.33) between the C-statistics of the training (0.918) and testing (0.924) cohorts when we included the TCI in the mortality model. Similarly, we found no significant difference between cohorts when using no measure of comorbidities and the alternative comorbidity measures (Table 4).

235 In the testing cohort, all methods of comorbidity measurement significantly increased the 236 C-statistic above a mortality model that lack any comorbidity measure (0.915). Inclusion of the 237 CCI and ECI produced C-statistics of 0.921 and 0.920, respectively, which were statistically 238 comparable to each other (p = 0.27). The C-statistic of the TCI model was significantly greater 239 than models with the CCI and ECI (p < 0.05). Models that included the TCI and all nineteen 240 comorbidities included separately (CIS) yielded the greatest C-statistics, 0.924 and 0.925 241 respectively. Those C-statistics were comparable (p = 0.11), but the CIS model included eighteen 242 more variables than the TCI model. A summary of the C-statistics for mortality models with each of the comorbidity measures is summarized in Table 5. 243

When comparing the model specification attributable to the comorbidity indices – CCI, ECI, and TCI – in the testing cohort, sensitivity was greatest for the model with the TCI (91.1%); whereas the models with the CCI and ECI had sensitivities of 90.9% and 90.8%, respectively; and the model that lacked any measure of comorbidity had a sensitivity of 90.3%. Accordingly, out of 1,201 deaths in the testing cohort, the TCI model accurately predicted 1,094; the CCI and
ECI models predicted 1,091 and 1,090 deaths, respectively; and the model without a comorbidity
measure predicted 1,084 deaths. When risk-stratified, each mortality model demonstrated that
observed mortality progressively increased across decile of expected mortality (Figure 1).
However, only the TCI score peaked in the tenth decile (that with the greatest mortality),
whereas the CCI and ECI scores peaked in the ninth decide and decreased in the tenth decile.

255 DISCUSSION

256 In this study of Indiana state adult trauma patients, we found that comorbidities, as 257 defined by the ACS National Trauma Data Standard, were exceedingly prevalent (65%), and the 258 measurement of comorbidities using any method significantly improved the statistical modelling 259 of in-hospital mortality. Inclusion of the TCI increased calibration of the mortality model in a 260 manner similar to the CCI and ECI, providing concurrent validity to the TCI approach. Although 261 the previously developed indices accounted for mortality-risk associated with comorbidities, the 262 TCI improved the model discrimination of that relationship, albeit slightly. That improvement 263 was evidenced by the increased number of deaths accurately predicted by the TCI model in 264 comparison to models with the other indices. Moreover, although the benefit of using the TCI 265 approach over other comorbidity indices was slight, it is notable that only the TCI score 266 corresponded directly with mortality among patients with the greatest risk, whereas the mean 267 scores of other comorbidity indices actually decreased from the ninth to the tenth decile of 268 expected mortality (Figure 1). This finding indicates that the TCI is calibrated so its score 269 reflects risk of mortality more closely than those of CCI and ECI. Therefore, we submit that at 270 the very least, investigators should consider the TCI approach to be a viable alternative to 271 develop a trauma-specific comorbidity index, rather than use more general comorbidity indices 272 when performing risk-adjustment to examine trauma mortality.

The TCI and CIS (the method currently employed by ACS TQIP) estimated the mortality-risk associated with comorbidities comparably, but the TCI afforded substantially more parsimony, reducing the required number of comorbidity-related variables from 19 to one. These findings have notable implications for risk-adjustment when examining both rare outcomes and small patient cohorts, instances when degrees of freedom must be used sparingly to preserve statistical power. Whereas in this study, we divided the overall study cohort into training and

testing cohorts, future studies need not perform this separate step of internal validation if the
Indiana weights for TCI externally validate in a national dataset. Therefore, future studies that
incorporate the TCI approach could retain all of the statistical power imparted by the full size of
their study cohort.

283 Unlike previously described comorbidity indices, the TCI uses comorbidity selection 284 specific to trauma registry datasets. As a result, the TCI potentially identifies pre-existing 285 conditions that one may not consider to be comorbidities in a conventional sense, such as the 286 presence of an advanced directive limiting care. However, we submit that such diagnoses are 287 both clinically relevant and designated as comorbidities by the ACS National Trauma Data 288 Standard. Conversely, the TCI does not include certain well-recognized comorbidities, such as 289 human immunodeficiency virus (HIV), if they are not included in the data or do not meet a 290 minimum threshold association with mortality. Specifically, regarding missing comorbidities, the 291 Charlson and Elixhauser comorbidity indices are widely used for risk-adjustment in trauma 292 outcomes research, however, those indices include diagnoses such as HIV that are not included 293 in the ACS National Trauma Data Standard. This discrepancy between the scoring systems and 294 trauma registry data inherently limits the performance of the scoring systems themselves as they were originally derived and validated. 295

296 The flexibility of comorbidity selection of the TCI approach is particularly advantageous 297 for the study of clinical registry data, which is subject to change over time or vary depending on 298 whether or not an institution adheres to the ACS National Trauma Data Standard. Moreover, the 299 TCI approach accounts for potential lapses in data quality, since it would exclude variables with 300 fields that are consistently omitted, as they would be unlikely to meet the minimum statistical 301 threshold of association with an outcome. As with other indices, the TCI approach achieves 302 parsimony by estimating the cumulative effect of multiple factors - comorbidities, in this case -303 as a single value. The combination of these attributes (model flexibility and parsimony) make the 304 TCI approach uniquely well-suited for the study of trauma subpopulations such as patients with 305 specific mechanisms of injury or hospitals that treat small numbers of injured patients, such as 306 non-trauma hospitals.

Although the TCI has certain advantages over other comorbidity indices, it also has
 limitations. Like other comorbidity indices, the TCI has no role in prospectively determining the
 expected outcomes of a given patient. Rather, the TCI was designed to enhance risk-adjusted

models used to examine trauma mortality retrospectively using clinical registry data. If the
Indiana-derived weights for TCI externally validate on a national dataset, then the Indiana TCI
can be used for future trauma registry risk-adjusted modeling.

313 If the Indiana TCI does not externally validate, we provide detailed methods of how to 314 conduct the TCI approach to either derive and validate more generalizable TCI weights using a 315 national dataset or use the TCI approach for project-specific derivation and internal validation. 316 Compared with other fixed-weight comorbidity indices, the TCI approach requires additional 317 steps for its calculation, specifically, the identification of statistically relevant comorbidities and the estimated association between those comorbidities and mortality. As a result, the TCI 318 319 approach does not assign fixed coefficients to comorbidities. Instead, the coefficients can be 320 derived from the particular dataset. Further, the TCI does not test for interaction effects or 321 collinearity between comorbidities and assumes a cumulative relationship between comorbidities 322 and mortality. Alternative methods, such as random forest regression, may address those shortcoming but would also add complexity to the calculation of a comorbidity index.²⁷ Despite 323 324 the limitations of the TCI, it is notable for its improved predictive modelling compared with 325 previously described comorbidity indices.

326 The results of this study should be interpreted in the context of its limitations. First, the 327 trauma population in Indiana may not be representative of the national trauma population. As 328 stated above, we do not propose to apply the coefficients for comorbidities reported in this study 329 to other populations without external validation. Instead, the purpose of this study is to detail the 330 approach for deriving the TCI. Further study, using national data, is necessary to externally 331 validate the Indiana-derived TCI weights, or derive nationally representative TCI coefficients for 332 comorbidities that can be applied more broadly. Second, the analyses are limited to in-hospital 333 mortality, a short-term outcome. In the process of deriving the TCI, we found that certain 334 comorbidities – current smoker, dementia, drug abuse disorder, and major psychiatric illness – 335 were actually associated with decreased mortality. Since this study is retrospective, the results do 336 not connote mechanisms for these relationships, and we do not intend to suggest that smoking, 337 for example, is protective overall, but simply associated with lower in-hospital mortality after 338 traumatic injury. The cumulative, long-term sequelae of smoking (e.g., peripheral vascular 339 disease, respiratory disease, and myocardial infarction) are clearly associated with an increased risk of mortality.^{28, 29} Regarding the association between psychiatric illnesses and decreased 340

mortality, our findings are consistent with other previously published work, but the influence of
 psychiatric illnesses on long-term mortality following trauma is still unclear.³⁰

In conclusion, this study provides a critical analysis of several methods previously used to measure the association of comorbidities and trauma outcomes, and it identifies limitations of those methods when applied to trauma registry data. In response to those shortcomings, this study details the development of the TCI approach, a method of measurement specifically designed for use with clinical registry data. When compared with other methods of measuring the clinical impact of comorbidities, the TCI approach demonstrated superior model discrimination and/or parsimony for estimating the risk of trauma mortality using Indiana state

350 trauma registry data.

351

352 ACKNOWLEDGEMENTS

The Indiana State Department of Health, Division of Trauma and Injury Prevention generouslyprovided access to data in support of this study.

355 356

REFERENCES

de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a
 critical review of available methods. J Clin Epidemiol. 2003 Mar;56(3):221-9. PubMed PMID:
 12725876. Epub 2003/05/03.

Feinstein AR. The Pre-Therapeutic Classification of Co-Morbidity in Chronic Disease. J
 Chronic Dis. 1970 Dec;23(7):455-68. PubMed PMID: 26309916. Epub 1970/12/01.

362 3. Hospital resources for optimal care of the injured patient. Prepared by a Task force of
 363 the Committee on Trauma of the American College of Surgeons. Bull Am Coll Surg. 1979
 364 Aug;64(8):43-8. PubMed PMID: 10243405. Epub 1979/07/11.

3654.Morris JA, Jr., MacKenzie EJ, Edelstein SL. The effect of preexisting conditions on

366 mortality in trauma patients. JAMA. 1990 Apr 11;263(14):1942-6. PubMed PMID: 2313871.

367 Epub 1990/04/11.

368 5. Ohmori T, Kitamura T, Ishihara J, Onishi H, Nojima T, Yamamoto K, Tamura R, Muranishi

369 K, Matsumoto T, Tokioka T. Early predictors for massive transfusion in older adult severe

370 trauma patients. Injury. 2017 May;48(5):1006-12. PubMed PMID: 28063676. Epub 2017/01/09.

371 6. Newgard CD, Fildes JJ, Wu L, Hemmila MR, Burd RS, Neal M, Mann NC, Shafi S, Clark DE,

372 Goble S, et al. Methodology and analytic rationale for the American College of Surgeons Trauma

373 Quality Improvement Program. J Am Coll Surg. 2013 Jan;216(1):147-57. PubMed PMID:

374 23062519. Epub 2012/10/16.

375 7. MacKenzie EJ, Hoyt DB, Sacra JC, Jurkovich GJ, Carlini AR, Teitelbaum SD, Teter H, Jr.

376 National inventory of hospital trauma centers. JAMA. 2003 Mar 26;289(12):1515-22. PubMed

377 PMID: 12672768. Epub 2003/04/04.

378 8. Statistics NCfH. International Classification of Diseases, Ninth Revision, Clinical

379 Modification (ICD-9-CM) [cited 2018]. Available from:

380 https://www.cdc.gov/nchs/icd/icd9cm.htm.

381 9. Health ISDo. ARTICLE 34. STATE TRAUMA REGISTRY 2013. Available from:

382 http://www.in.gov/legislative/iac/20131120-IR-410120617FRA.xml.pdf.

383 10. Indiana Patient Registry [Internet]. Available from: <u>https://www.in.gov/isdh/25407.htm</u>
384 (Accessed November 1, 2019).

385 11. Calland JF, Nathens AB, Young JS, Neal ML, Goble S, Abelson J, Fildes JJ, Hemmila MR.

386 The effect of dead-on-arrival and emergency department death classification on risk-adjusted

387 performance in the American College of Surgeons Trauma Quality Improvement Program. J

388 Trauma Acute Care Surg. 2012 Nov;73(5):1086-91; discussion 91-2. PubMed PMID: 23117375.

389 Epub 2012/11/03.

390 12. Association AH. AHA Annual Survey of Hospitals. 2013-2016.

391 13. Health ISDo. State of Indiana Trauma Registry Data Dictionary 2015 [January 19, 2019].
392 Available from:

393 https://www.in.gov/isdh/files/NEW VERSION 2015 Indiana Data Dictionary.pdf

14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic

395 comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-

396 83. PubMed PMID: 3558716. Epub 1987/01/01.

397 15. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with

administrative data. Med Care. 1998 Jan;36(1):8-27. PubMed PMID: 9431328. Epub

399 1998/02/07.

400 16. Trauma ACoSCo. National Trauma Data Standards Data Dictionary - 2014.

401 https://wwwdshstexasgov/injury/registry/Data-Dictionaries/2014NTDSDataDictionarypdf,

402 Accessed March 2021.

403 17. Trauma ACoSCo. National Trauma Data Standards Data Dictionary - 2015.

404 <u>https://wwwfacsorg/-/media/files/quality-programs/trauma/ntdb/ntds/data-dictionaries/ntds-</u>

- 405 <u>data-dictionary-2015ashx</u> Accessed March 2021.
- 406 18. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the
- 407 Elixhauser comorbidity measures into a point system for hospital death using administrative
- 408 data. Med Care. 2009 Jun;47(6):626-33. PubMed PMID: 19433995. Epub 2009/05/13.

409 19. Mickey RM, Greenland S. The impact of confounder selection criteria on effect

410 estimation. Am J Epidemiol. 1989 Jan;129(1):125-37. PubMed PMID: 2910056. Epub

411 1989/01/01.

412 20. Zhang Z. Model building strategy for logistic regression: purposeful selection. Ann Transl

413 Med. 2016 Mar;4(6):111. PubMed PMID: 27127764. Pubmed Central PMCID: PMC4828741.

414 Epub 2016/04/30.

415 21. Afifi RBBaAA. Comparison of Stopping Rules in Forward "Stepwise" Regression. Journal
416 of the American Statistical Association. 1977;72(357):46-53.

417 22. Pregibon D. Logistic Regression Diagnostics. The Annals of Statistics. 1981;9(4):705–24.

418 23. Stef van Buuren KG-O. MICE: Multivariate Imputation by Chained Equations in R. Journal
419 of Statistical Software. 2011;45(3):1-67.

420 24. Xu Y, Goodacre R. On Splitting Training and Validation Set: A Comparative Study of

421 Cross-Validation, Bootstrap and Systematic Sampling for Estimating the Generalization

422 Performance of Supervised Learning. J Anal Test. 2018;2(3):249-62. PubMed PMID: 30842888.

- 423 Pubmed Central PMCID: PMC6373628. Epub 2018/01/01.
- 424 25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more
- 425 correlated receiver operating characteristic curves: a nonparametric approach. Biometrics.
- 426 1988 Sep;44(3):837-45. PubMed PMID: 3203132. Epub 1988/09/01.
- 427 26. Buis ML. Discrete uses for uniform(). The Stata Journal. 2007;7(3):434–5.

428 27. Bertsimas D, Dunn J, Velmahos GC, Kaafarani HMA. Surgical Risk Is Not Linear:

429 Derivation and Validation of a Novel, User-friendly, and Machine-learning-based Predictive

430 OpTimal Trees in Emergency Surgery Risk (POTTER) Calculator. Ann Surg. 2018 Oct;268(4):574-

431 83. PubMed PMID: 30124479. Epub 2018/08/21.

432 28. Trap-Jensen J. Effects of smoking on the heart and peripheral circulation. Am Heart J.

433 1988 Jan;115(1 Pt 2):263-7. PubMed PMID: 3276115. Epub 1988/01/01.

434 29. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects

435 of smoking. Chest. 2007 May;131(5):1557-66. PubMed PMID: 17494805. Epub 2007/05/15.

436 30. Townsend LL, Esquivel MM, Uribe-Leitz T, Weiser TG, Maggio PM, Spain DA, Tennakoon

437 L, Staudenmayer K. The prevalence of psychiatric diagnoses and associated mortality in

438 hospitalized US trauma patients. J Surg Res. 2017 Jun 1;213:171-6. PubMed PMID: 28601311.

439 Epub 2017/06/12.

440

Author Man

	All patients	Training	Testing	p-value*
	(N=84,903)	Cohort	Cohort	
		(n=42,451)	(n=42,452)	
Age, years (%)				0.37
16-24	10.77	10.69	10.85	
25-34	10.30	10.30	10.30	
35-44	9.17	9.07	9.26	
45-54	11.34	11.41	11.27	
55-64	13.19	13.15	13.23	
65-74	13.03	13.14	12.92	
>=75	32.18	32.21	32.16	
Race (%)				0.20
White	84.88	84.77	84.98	
Black	8.98	8.92	9.03	
Other	1.97	1.98	1.96	
NA/not known	3.55	3.66	3.45	
Female (%)	47.05	46.97	47.12	0.06
Payer type (%)				0.22
Private/commercial	25.29	25.53	25.06	
Medicaid	6.70	6.55	6.86	
Medicare	39.61	39.70	39.51	
Other	20.13	19.98	20.28	
NA/not known	8.17	8.16	8.18	
Mechanism (%)				0.40
Adverse reaction/overdose/poisoning	0.54	0.55	0.53	
Assault	6.30	6.29	6.30	
Burn/electrocution	1.90	1.88	1.92	
Cut/pierce	1.56	1.53	1.59	
Fall	53.74	53.71	53.77	

Table 1. Patient characteristics

Firearm	1.11	1.08	1.14	
Hanging/asphyxiation/drowning	0.14	0.13	0.15	
Machinery	0.96	0.95	0.96	
Motor vehicle accident	22.11	22.01	22.20	
Natural	0.04	0.05	0.02	
Other/not known	2.68	2.65	2.70	
Overexertion	0.26	0.29	0.24	
Pedestrian/pedestrian cyclist/	2.83	2.92	2.74	
pedestrian struck				
Struck by/against	2.70	2.81	2.60	
Transport	0.68	0.69	0.68	
Injury Severity Score, mean (SD)	8 (7)	8 (7)	8 (7)	0.33
Initial Systolic Blood Pressure, mean	142 (27)	142 (27)	142 (27)	0.17
(SD)				
Initial Heart Rate, mean (SD)	86 (19)	86 (19)	86 (19)	0.70
Glasgow coma scale, mean (SD)	14 (3)	14 (3)	14 (3)	0.44
Inter-hospital transfer (%)	18.99	19.05	19.94	0.19
American College of Surgeons trauma				0.93
verification level (%)				
I	16.60	16.61	16.60	
П	30.32	30.27	30.36	
Ш	7.24	7.19	7.28	
Non-trauma center	45.84	45.93	45.76	
Hospital beds				0.28
<200	56.35	56.02	56.64	
201-400	25.77	25.87	25.66	
401-600	6.41	6.49	6.33	
>600	11.49	11.62	11.36	
Teaching	69.42	69.60	69.25	0.28
Non-profit	91.92	91.95	91.88	0.64

*Chi-square used to calculate p-values for categorical variables, and t-test used to calculate p-values for continuous variables

Author Manuscr

	All patients	Training	Testing	p-value*
	(N=84,903)	Cohort	Cohort	
		(n=42,451)	(n=42,452)	
Advanced directive	1.23	1.16	1.30	0.06
Bleeding disorder	6.96	7.03	6.89	0.42
Chemotherapy	0.36	0.35	0.36	0.86
Chronic obstructive pulmonary	8.08	8.01	8.15	0.48
disease				
Chronic renal failure	2.08	2.00	2.15	0.14
Cirrhosis	0.62	0.62	0.62	1.00
Congestive heart failure	5.70	5.66	5.74	0.65
Current smoker	20.21	19.97	20.46	0.08
Dementia	5.75	5.86	5.63	0.17
Diabetes Mellitus	15.84	15.89	15.79	0.69
Disseminated cancer	0.89	0.86	0.93	0.29
Drug use disorder	2.55	2.60	2.49	0.31
Functionally dependent	3.74	3.72	3.75	0.82
History of myocardial infarction	14.01	13.86	14.15	0.21
History of myocardial infarct within	0.85	0.90	0.81	0.18
last six months				
History of peripheral vascular disease	0.63	0.62	0.63	0.83
Hypertension	24.80	24.96	24.63	0.28
Major psychiatric illness	4.69	4.60	4.78	0.21
Steroid use	0.61	0.62	0.60	0.79

Table 2. Prevalence of comorbidities used to develop trauma comorbidity index and comparison between training and testing cohorts (%)

*Chi-square used to calculate p-value

Table 3. p-values from bivariate regression and risk-adjusted coefficients used to develop the trauma comorbidity index (TCI) with mortality as the outcome and coefficients for the Charlson and Elixhauser comorbidity indices (CCI, and ECI) for corresponding comorbidities

–	p-value	Coefficient		
0		TCI	CCI	ECI
Advanced directive	< 0.001	1.24		
Bleeding disorder	< 0.001	0.86		1
Chemotherapy	0.02	1.02		
Chronic obstructive pulmonary disease	< 0.001	0.45	1	1
Chronic renal failure	0.07	0.44	2	1
Cirrhosis	0.05	0.91	3	1
Congestive heart disease	< 0.001	0.87	1	1
Current smoker	< 0.001	-0.41		
Dementia	0.003	-0.01	1	
Diabetes Mellitus	0.05	0.22	1	1
Disseminated cancer	0.003	0.75	6	1
Drug use disorder	0.17	-1.04		1
Functionally dependent	< 0.001	0.32		
History of myocardial infarction	0.05	0.15	1	
History of myocardial infarct within last	0.20	0.53	1	
six months				
History of peripheral vascular disease	0.20	0.75	1	1
Hypertension	0.11	0.09		1
Major psychiatric illness	0.22	-0.31		
Steroid use	0.002	0.78		

"--" not included in index

* Coefficients with positive values denote an association with increased mortality and negative values indicate an association with decreased mortality.

Table 4. Comparison of mortality models with different comorbidity measures between training and testing cohorts

Method of measurement	Training cohort, c-statistic	Testing cohort, c-statistic	p-value
NCI	0.909	0.915	0.32
CCI	0.913	0.921	0.16
ECI	0.914	0.920	0.29
TCC	0.914	0.920	0.25
CIS	0.918	0.925	0.23
TCI	0.918	0.924	0.33

*NCI = no comorbidities included; CCI = Charleson comorbidity index; ECI = Elixhauser comorbidity index; TCC = cumulative count of trauma comorbidities; CIS = comorbidities included separately; TCI = trauma comorbidity index

Author Man

Method of measurement	NCI	CCI	ECI	TCC	CIS	TCI
(c-statistic)	(0.915)	(0.921)	(0.920)	(0.921)	(0.925)	(0.924)
NCI (0.915)						
CCI (0.921)	< 0.001					
ECI (0.920)	< 0.001	0.27				
TCC (0.921)	< 0.001	0.42	0.72			
CIS (0.925)	< 0.001	0.005	0.001	0.001		
TCI (0.924)	< 0.001	0.03	0.003	0.003	0.11	

Table 5. Comparison of c-statistic of mortality models with different comorbidity measures in the testing cohort, p-value

*NCI = no comorbidities included; CCI = Charleson comorbidity index; ECI = Elixhauser comorbidity index; TCC = cumulative count of trauma comorbidities; CIS = comorbidities included separately; TCI = trauma comorbidity index



Comparison of observed and expected mortality using different comorbidity indices with corresponding comorbidity index scores

* CCI = Charlson comorbidity index; ECI = Elixhauser comorbidity index; TCI = trauma comorbidity index

** Expected mortality is stratified by decile of risk-adjusted, predicted mortality "----" = Comorbidity index score, mean calculated per decile of expected mortality